Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of ...

A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...

Find insights on AstraZeneca, Incyte and more in the latest Market Talks from the health-care sector.

Assetmark Inc. raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 32.9% in the 4th quarter, ...

Ascendis Health's journey from near-bankruptcy to profitability showcases how strategic leadership and financial discipline ...

J.P. Morgan analyst Jessica Fye maintained a Buy rating on Insmed (INSM – Research Report) on March 14 and set a price target of $90.00. The ...

Check Out Our Latest Analysis on Ascendis Pharma A/S Ascendis Pharma A/S Price Performance NASDAQ:ASND opened at $138.18 on Tuesday. The stock has a market cap of $8.39 billion, a P/E ratio of -19 ...

Once written off as a lost cause by most, Ascendis Health – which specialises in wellness products and medical devices – has achieved an improbable recovery. However, while coming back from ...

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company with a $9.07 billion market capitalization focused on developing transformative therapies for rare endocrine disorders, has been ...

European equities traded in the US as American depositary receipts kicked off the week higher late Monday morning, rising 1.12% to 1,433.84 on the S&P Europe Select ADR Index. From continental Europe, ...

Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company with a $9.07 billion market capitalization focused on developing transformative therapies for rare endocrine disorders, has been ...